BRPI0921454A2 - métodos para tratar um paciente com câncer, e para identificar células tronco cancerosas - Google Patents

métodos para tratar um paciente com câncer, e para identificar células tronco cancerosas

Info

Publication number
BRPI0921454A2
BRPI0921454A2 BRPI0921454A BRPI0921454A BRPI0921454A2 BR PI0921454 A2 BRPI0921454 A2 BR PI0921454A2 BR PI0921454 A BRPI0921454 A BR PI0921454A BR PI0921454 A BRPI0921454 A BR PI0921454A BR PI0921454 A2 BRPI0921454 A2 BR PI0921454A2
Authority
BR
Brazil
Prior art keywords
treating
methods
stem cells
cancer
identifying
Prior art date
Application number
BRPI0921454A
Other languages
English (en)
Inventor
Robert E Reiter
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BRPI0921454A2 publication Critical patent/BRPI0921454A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI0921454A 2008-11-10 2009-11-10 métodos para tratar um paciente com câncer, e para identificar células tronco cancerosas BRPI0921454A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/268,302 US8663635B2 (en) 2006-03-21 2008-11-10 N-cadherin: target for cancer diagnosis and therapy
PCT/US2009/063921 WO2010054397A2 (en) 2008-11-10 2009-11-10 N-cadherin: target for cancer diagnosis and therapy

Publications (1)

Publication Number Publication Date
BRPI0921454A2 true BRPI0921454A2 (pt) 2016-01-05

Family

ID=42153657

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921454A BRPI0921454A2 (pt) 2008-11-10 2009-11-10 métodos para tratar um paciente com câncer, e para identificar células tronco cancerosas

Country Status (13)

Country Link
US (2) US8663635B2 (pt)
EP (1) EP2355850A4 (pt)
JP (1) JP2012508259A (pt)
KR (1) KR20110084528A (pt)
CN (1) CN102271709A (pt)
AU (1) AU2009313197A1 (pt)
BR (1) BRPI0921454A2 (pt)
CA (1) CA2743133A1 (pt)
CO (1) CO6382138A2 (pt)
IL (1) IL212800A0 (pt)
MX (1) MX2011004979A (pt)
RU (1) RU2011123654A (pt)
WO (1) WO2010054397A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278821A1 (en) * 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US20090130108A1 (en) * 2006-03-21 2009-05-21 The Regents Of The University Of California N-Cadherin and Ly6 E: Targets for Cancer Diagnosis and Therapy
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
AU2009231570A1 (en) * 2008-04-04 2009-10-08 The Regents Of The University Of California Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
US8703920B2 (en) * 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin
US20140274872A1 (en) * 2013-03-15 2014-09-18 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
CN108540664B (zh) * 2018-03-30 2021-02-19 联想(北京)有限公司 一种开机方法及电子设备
CN112384806B (zh) * 2018-08-03 2024-07-09 西托根有限公司 癌症的骨转移诊断用组成物及包括其的试剂盒

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889157A (en) * 1990-10-12 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Humanized B3 antibody fragments, fusion proteins, and uses thereof
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6277824B1 (en) * 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
WO2001062206A2 (en) 2000-02-22 2001-08-30 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
DE10008907A1 (de) 2000-02-25 2001-08-30 Haarmann & Reimer Gmbh Topische kosmetische Mittel enthaltend benzokondensierte oder heterocyclisch kondensierte 2-Hydrazino-1,3-heteroazole
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
US8784821B1 (en) 2003-05-31 2014-07-22 Amgen Research (Munich) Gmbh Human-anti-human cd3 binding molecules
AU2004303585B2 (en) 2003-12-22 2010-12-23 Glaxo Group Limited NOGO-a neutralising immunoglobulins for treatment of neurological diseases
EP1786463A4 (en) * 2004-03-26 2009-05-20 Human Genome Sciences Inc ANTIBODY AGAINST NOGO RECEPTOR
JP2008546387A (ja) * 2005-06-13 2008-12-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US20100278821A1 (en) * 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US20090130108A1 (en) * 2006-03-21 2009-05-21 The Regents Of The University Of California N-Cadherin and Ly6 E: Targets for Cancer Diagnosis and Therapy
US8559186B2 (en) 2008-04-03 2013-10-15 Qualcomm, Incorporated Inductor with patterned ground plane
AU2009231570A1 (en) * 2008-04-04 2009-10-08 The Regents Of The University Of California Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
US8703920B2 (en) 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin
EP2603521A4 (en) 2010-08-12 2014-10-01 Attogen Inc ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES

Also Published As

Publication number Publication date
US20140220005A1 (en) 2014-08-07
US20100119527A1 (en) 2010-05-13
WO2010054397A3 (en) 2010-08-19
US8663635B2 (en) 2014-03-04
US9470689B2 (en) 2016-10-18
CO6382138A2 (es) 2012-02-15
IL212800A0 (en) 2011-07-31
RU2011123654A (ru) 2012-12-20
JP2012508259A (ja) 2012-04-05
EP2355850A4 (en) 2012-07-18
CA2743133A1 (en) 2010-05-14
AU2009313197A1 (en) 2011-07-07
CN102271709A (zh) 2011-12-07
WO2010054397A2 (en) 2010-05-14
EP2355850A2 (en) 2011-08-17
KR20110084528A (ko) 2011-07-25
MX2011004979A (es) 2011-09-01

Similar Documents

Publication Publication Date Title
BRPI0915773A2 (pt) stent, válvula, e, método para tratar um paciente
BRPI0818287A2 (pt) células dendríticas manipuladas e usos para o tratamento do câncer.
PT3185012T (pt) Método para identificação, seleção e análise de células tumorais
BRPI0910969A2 (pt) dispositivo, método para preparar em dispositivo, e, método para tratar um paciente
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
BRPI0817664A2 (pt) Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
BRPI0912337A2 (pt) composto método para melhorar memória em paciente, e, método para tratar condições
BRPI0821168A2 (pt) anticorpo, hibridoma, e, métodos para tratar doenças em um paciente e para tratar um paciente de transplante
IL233023A (en) Method of characterizing a cancer in a subject
BRPI0910608A2 (pt) métodos e sistemas para avaliar resultados clínicos
SI3120869T1 (sl) Nova imunoterapija proti več tumorjem, vključno z nevronalnimi in možganskimi tumorji
BRPI0807755A2 (pt) Sementes revestidas e métodos para fabricação de sementes revestidas.
BRPI1014229A2 (pt) método para prover desenvolvimento do gerenciamento de terapia, e, plataforma de desenvolvimento de gerenciamento de terapia
BRPI0817917A2 (pt) Implemento para cuidado oral, e, método para formar um implemento para cuidado oral
BRPI0820212A2 (pt) Dispositivo para tratamento de fraturas, método para tratamento de fraturas, e, kit para tratamento de fraturas
BRPI0907036A2 (pt) Conjunto de máscara para fornecer gás para um paciente, e, kit de conjunto de máscara para fornecer um gás para um paciente.
BRPI0817751A2 (pt) método para suprimir a proliferação de células de tumor, e, composição
BRPI1010937A2 (pt) composto, uso de um composto, e, método para tratar câncer
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI0916472A2 (pt) dispositivo de tratamento de ferimento, método para tratamento de um ferimento e dispositivo de tratamento de ferimento
BRPI0921454A2 (pt) métodos para tratar um paciente com câncer, e para identificar células tronco cancerosas
BRPI0905851A2 (pt) Métodos, sistemas, e dispositivos para realizar procedimentos eletrocirúrgicos
BRPI0916787A2 (pt) artigo, e, método para fabricar um artigo
BRPI0918642A2 (pt) coque e método para fabricação do mesmo.
BRPI1007779A2 (pt) perexilina, método para tratamento de hcm, programa de tratamento para tratar hcm e uso da perexilina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]